Canada markets closed
  • S&P/TSX

    21,188.19
    +101.20 (+0.48%)
     
  • S&P 500

    4,536.19
    +16.56 (+0.37%)
     
  • DOW

    35,609.34
    +152.03 (+0.43%)
     
  • CAD/USD

    0.8116
    +0.0025 (+0.31%)
     
  • CRUDE OIL

    84.25
    +1.29 (+1.55%)
     
  • BTC-CAD

    81,129.57
    +1,479.38 (+1.86%)
     
  • CMC Crypto 200

    1,539.25
    +58.45 (+3.95%)
     
  • GOLD FUTURES

    1,782.90
    +12.40 (+0.70%)
     
  • RUSSELL 2000

    2,289.77
    +13.85 (+0.61%)
     
  • 10-Yr Bond

    1.6360
    +0.0010 (+0.06%)
     
  • NASDAQ

    15,121.68
    -7.41 (-0.05%)
     
  • VOLATILITY

    15.49
    -0.21 (-1.34%)
     
  • FTSE

    7,223.10
    +5.57 (+0.08%)
     
  • NIKKEI 225

    29,255.55
    +40.03 (+0.14%)
     
  • CAD/EUR

    0.6965
    +0.0014 (+0.20%)
     

XORTX Announces New Clinical Advisory Board Member

·2 min read

CALGARY, Alberta, Aug. 31, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biotechnology company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the addition of one new member to the Company’s clinical advisory board, Dr. Charles Edelstein.

Dr. Allen Davidoff stated, “The appointment of Dr. Edelstein to XORTX’s clinical advisory board will be important in the future development of our clinical programs in autosomal dominant polycystic kidney disease and in acute kidney injury. Dr. Edelstein brings substantial professional experience as a thought leader, combined with clinical experience treating patients with autosomal dominant polycystic kidney disease and acute kidney injury. We are honored to have Dr. Edelstein join our esteemed clinical advisory board and look forward to the valuable contributions that Charles can bring to our kidney disease programs to treat progressive kidney disease. XORTX’s clinical advisory board now includes Nephrologists - Dr. Petter Bjornstad, Dr. Richard Johnson, Dr. Anjay Rastogi as well as Cardiologists - Dr. Federico Maese, and Dr. Henk ter Keurs.”

Dr. Charles Edelstein, MD PhD is Professor of Medicine and Nephrologist at the University of Colorado, Denver. Dr. Edelstein is board certified in Nephrology and has a doctoral degree (PhD) in Internal Medicine. He did his Internal Medicine residency and Nephrology fellowship at University of Stellenbosch and University Cape Town Medical School, respectively. His academic research focuses on both therapeutic studies in animal models of polycystic kidney disease (PKD) as well as acute kidney injury (AKI) and biomarkers of AKI. Dr. Edelstein is a world leader in PKD research and PKD care and has received an award for the WSCI Outstanding Investigator Award and is a former president of the Western Section of the American Federation of Clinical Research and International Society of nephrology member and American Society of Nephrology Advisory Committee Member.

Dr. Edelstein commented, “I am thrilled for the opportunity to advise XORTX in developing new therapies for PKD and AKI.”

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a biotechnology company with three clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney injury secondary to Coronavirus / COVID-19 infection and XRx-225, a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). The Company has intellectual property rights and has established proof of concept through independent clinical studies. XORTX is working to advance its clinical development stage products that target xanthine oxidase to inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future of patients suffering from kidney disease. Additional information on XORTX Therapeutics is available at www.xortx.com.

For further information, please contact:

Allen Davidoff, CEO

Nick Rigopulos, Director of Communications

adavidoff@xortx.com or +1 403 455 7727

nick@alpineequityadv.com or +1 617 901 0785

The CSE has neither approved nor disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, beliefs or expectations regarding the future. Although the Company believes that any such intentions, plans, estimates, beliefs and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs and expectations will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements. The Company assumes no obligations to update any forward looking statements, whether as a result of new information, future events or otherwise.



Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting